If you've heard about retatrutide and are wondering if it really helps with weight loss, here's the most comprehensive guide to get you up to speed. This experimental drug from Eli Lilly is in the spotlight for its potent action on three hormonal pathways related to appetite and metabolism, and for trial data that show it differs from current medications. In the following lines, we'll tell you what it is, how it works, what results it has shown, and what you should consider before getting too excited. You'll also find comparisons with semaglutide and tirzepatide and a clear explanation of its regulatory status. All of this is presented with a practical approach and in plain Spanish, so you don't miss a thing.
First and foremost, it's important to clarify the starting point: retatrutide is not yet approved by regulatory agencies and can only be used in clinical trials. Even so, the data published and presented at conferences are striking, with weight losses approaching 24% in less than a year in obese adults without diabetes. This potential is explained by its "triple" mechanism of action and by additional metabolic effects that extend beyond weight loss. In any case, we are talking about a potent treatment that requires medical supervision and a gradual dosing strategy to improve tolerance, because gastrointestinal side effects do occur and are dose-dependent, although most are mild to moderate.
What is retatrutide and how does it work?
Retatrutide (LY-3437943) is a "triple" agonist designed to simultaneously activate GLP-1, GIP, and glucagon receptors. This combination is not accidental: mimicking these intestinal and pancreatic hormones aims to reduce appetite, slow gastric emptying, and increase energy expenditure —a triple impact that can translate into greater weight loss and a healthier cardiometabolic profile. Developed by Eli Lilly, the molecule attempts to leverage the best of three worlds that we already know separately with single- or dual-target drugs.
The physiological logic is sound. GLP-1 analogs regulate blood sugar and promote satiety; GIP agonism appears to add an extra metabolic component; and glucagon receptor stimulation may promote thermogenesis and substrate mobilization. Together, these effects aim to encourage eating less, feeling less hungry, and burning more energy . It's no wonder, then, that the Phase 2 studies have generated headlines.
Clinical trials: how much weight is lost and what happens to metabolic health
In a Phase 2 trial in overweight or obese adults without diabetes, the highest dose evaluated (12 mg) achieved an average weight loss of approximately 24% at 48 weeks . The magnitude and rate of this loss surprised even the researchers, who noted that many participants had not even reached a weight plateau by the end of the study, suggesting that the efficacy ceiling may be somewhat higher with longer treatment duration.
In addition to weight loss, there was a notable impact on cardiometabolic markers: triglyceride reductions of up to 40% , apoC-III levels of around 38%, decreased liver fat, improved blood pressure, and signs of increased insulin sensitivity were reported. In some analyses, women achieved weight loss of up to 29% , a striking figure that reinforces the idea that triple action could offer an added benefit in certain profiles.
The data isn't limited to people without diabetes. In a study of patients with type 2 diabetes, participants treated with retatrutide lost around 17% of their body weight over nine months , and approximately one-third normalized their blood glucose levels during treatment. This is significant because achieving similar weight loss is often more difficult in type 2 diabetes. In the placebo group, by the way, the weight loss was around 2,1%, highlighting the difference between active intervention and control.
Finally, one response statistic deserves mention: up to 83% of those who received the highest dose achieved a ≥15% weight loss from baseline. These are clinically significant thresholds that correlate with relevant improvements in cardiometabolic risk.
Dosage and guidelines: why start low and increase slowly
In Phase 2, weekly doses of 1, 4, 8, and 12 mg were tested, but most participants did not start directly with the target dose. A starting strategy of 2 mg/week with gradual escalations was chosen to promote tolerance, especially regarding gastrointestinal effects. This gradual approach reduced dropout rates and improved adherence.
How does this translate in practice? In the absence of an official data sheet (because it is not yet approved), the most logical dosage regimens resemble this example: 2 mg for weeks 1–4 ; 4 mg for weeks 5–8; then adjust to 8 or 12 mg based on tolerability and response. In studies, dose increases were associated with a higher incidence of gastrointestinal side effects, so the titration rate should be individualized.
An important point regarding frequency: much of the documentation and press releases have described weekly administration . However, some news articles mentioned a bi-weekly schedule. Given that the published protocols detail weekly regimens, it seems likely that this will be the standard, although we will have to wait for the complete Phase 3 results and the regulatory decision to know the final dosage.
Safety and adverse effects: what is already known
The overall safety profile of retatrutide, based on Phase 2 data, is comparable to that of related drugs. The most frequent adverse events have been nausea, vomiting, diarrhea, and constipation , typical of this class of medications and more likely with high doses or during dose escalation. Headache, fatigue, and transient elevations of liver enzymes , generally mild to moderate in intensity, have also been observed .
Some trial reports indicated increases in heart rate and conduction disturbances that were not considered serious. As with any incretin agonist, the key lies in gradual titration and close clinical monitoring, modulating the rate of dose increase and implementing dietary measures to mitigate gastrointestinal symptoms.
It's important to put this in context with comparator drugs. Semaglutide, for example, shares many of these effects, and authorities have also reported rare cases of non-arteritic anterior ischemic optic neuropathy . Again, these are infrequent situations, but they illustrate why monitoring and patient education are essential in chronic weight-loss therapies.
Availability, regulatory status and expected times
As of today—based on information from July 2025—retatrutide is not approved by either the FDA or European agencies. Therefore, its use is limited to controlled clinical trials, where it is legal and follows established protocols. The company presented Phase 2 analyses at the 2023 ADA Annual Meeting (June 23–26) and has ongoing programs to confirm efficacy and safety in larger populations.
When might it arrive? Public projections vary: some sources speculate about late 2025 or early 2026 , while others place the timeframe between 2026 and 2027. Until Phase 3 trials are completed and the benefit-risk balance is assessed, there will be no approval. If someone offers to "get it" outside of a clinical trial, be wary: it is not yet authorized for commercial use.
Retatrutide versus semaglutide and tirzepatide
Semaglutide is a GLP-1 receptor agonist with a long history of use. It was approved in 2017 for diabetes and, since 2021, has been indicated for chronic weight management . In adults without diabetes, it can achieve approximately 15% weight loss over 68 weeks . Its most common adverse effects are gastrointestinal (nausea, vomiting, diarrhea), and events such as pancreatitis or gastroparesis have been reported, in addition to the previously mentioned NAION warning.
Tirzepatide combines GLP-1 and GIP agonism. It has approvals in the United States and Europe (initially for diabetes; later, for obesity as Zepbound). Trials such as SURPASS have shown dropout rates of up to 20% over 72 weeks , and although its tolerability profile is similar to that of GLP-1, higher dropout rates have been observed at higher doses (e.g., with 15 mg), a detail to consider in clinical practice.
Based on the available preliminary data, retatrutide appears to be the most effective for average weight loss, followed by tirzepatide and then semaglutide. Furthermore, there are indications that it offers broader metabolic benefits (lipids, liver fat, insulin sensitivity). However, it is important to remember that retatrutide is still in the confirmatory phase and cannot be directly compared until head-to-head trials or robust meta-analyses with standardized criteria are available.
Who could benefit and what do the clinics expect?
The profiles that could benefit most from this type of therapy are adults with obesity or obesity with comorbidities , especially those who have not responded to GLP-1 analogues or dual agonists. In people with type 2 diabetes, the dual impact on blood glucose and weight is also a significant advantage. Even so, the plan must be individualized: there are differences in tolerance, comorbidities to consider, and clinical priorities (for example, fatty liver, hypertension, or dyslipidemia).
While awaiting approval, many specialized centers are preparing protocols for their future implementation, some even in large metropolitan areas of the United States. In Spain, weight management teams like the MediQuo Weight Loss Clinic are committed to personalized approaches, sometimes including auriculotherapy for weight loss , with nutritional, behavioral, and medical follow-up—an essential foundation to complement any pharmacological treatment. If you are interested in a professionally guided approach, you can find more information at www.mediquo.com/clinica-perdida-de-peso.
Practical user guide: key concepts before you begin
As a potent medication, retatrutide requires a strategic approach. Based on clinical trials, the most reasonable approach is to start at 2 mg/week and gradually increase the dose, monitoring gastrointestinal symptoms, hydration, and dietary guidelines (small meals, low fat, prioritizing protein) during the increases. If an increase significantly worsens tolerance, the previous dose can be maintained for several weeks before attempting the next step.
The target dosage (4, 8, or 12 mg) will depend on your response and the number of side effects you experience. Ultimately, the "sweet spot" is the lowest dose that allows you to lose weight sustainably without compromising your quality of life. Based on current evidence, there are no shortcuts: maintaining lifestyle changes remains essential for consolidating results and protecting muscle mass.
FAQ
What is the typical starting dose? In Phase 2, most people started with 2 mg weekly and stepped up to 4, 8, or 12 mg. This low start reduces nausea and other GI effects associated with rapid increases.
How often is it administered? Trial documentation describes a weekly schedule . Some popular publications mentioned bi-weekly administration, but detailed protocols have been weekly; we will have to wait for the approved dosage to confirm.
Is it approved today? No. Retatrutide is still under investigation and is not authorized by the FDA or European agencies. Its use should be limited to clinical trials. Some public projections place possible approval between the end of 2025 and 2027, provided the Phase 3 data are favorable.
Is it better than semaglutide? Phase 2 studies suggest greater weight loss in less time compared to semaglutide. However, direct comparisons and long-term data with the already approved retatrutide (when it becomes available) are lacking to definitively say so.
And how does it compare to tirzepatide (Mounjaro/Zepbound)? Tirzepatide is dual-action (GLP-1/GIP), while retatrutide is triple-action (GLP-1/GIP/glucagon). Preliminary data favor retatrutide in terms of percentage weight loss , but again, comparative trials and real-world experience will be needed.
Does it work for “belly fat”? Trials have shown reductions in total body and liver fat, with significant weight loss. The exact distribution of weight loss (abdomen vs. other areas) may vary from person to person, but improvements in waist circumference and metabolic markers support benefits in visceral fat reduction.
Is it legal to obtain it outside of clinical trials? Its use is only legal in clinical research. Any alternative channel outside of that setting is risky and potentially fraudulent.
Is Retatrutide the same as Mounjaro (tirzepatide)? No. They are similar in acting on GLP-1 and GIP, but retatrutide adds glucagon receptor agonism , which could explain some of the additional efficacy observed.
Advantages and limitations today
Among the most notable advantages are greater weight loss in less time , a wide range of metabolic benefits (lipids, fatty liver, blood pressure, insulin sensitivity), and signs of better preservation of muscle mass in some participants. This combination suggests a more comprehensive approach to obesity that goes beyond simply "seeing the scale go down."
On the limitations side, it is not yet approved , long-term data are lacking, and tolerability is variable, with GI effects that may require slower dose escalation. Furthermore, as with all obesity pharmacotherapy, its best performance is achieved when combined with healthy eating habits, physical activity, and sleep, along with behavioral support.
If you're considering a medication-assisted approach, look for teams with experience in obesity medicine and a clear follow-up protocol. Both nationally and internationally, there are already clinics preparing to implement new therapies once they are approved, and weight-loss services like MediQuo can be the starting point for developing a personalized plan while maintaining clinical oversight.
The overall picture painted by the trials is optimistic: retatrutide currently leads in relative efficacy compared to tirzepatide and semaglutide in adults without diabetes, offering significant metabolic benefits. Its Achilles' heel, as always in this class, is digestive tolerance and the need for dose escalation . The key to any innovation is still missing: Phase 3 confirmation and real-world experience with the product information available. Until then, patience, a critical mind, and professional guidance are the best combination for navigating this promising yet demanding field with confidence.